- Home
- CMPX vs PROK Comparison
CMPX vs PROK Comparison
Compare CMPX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- PROK
- Stock Information
- Founded
- CMPX 2014
- PROK 2015
- Country
- CMPX United States
- PROK United States
- Employees
- CMPX N/A
- PROK N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPX Health Care
- PROK Health Care
- Exchange
- CMPX Nasdaq
- PROK Nasdaq
- Market Cap
- CMPX 206.3M
- PROK 237.4M
- IPO Year
- CMPX N/A
- PROK N/A
- Fundamental
- Price
- CMPX $1.42
- PROK $1.54
- Analyst Decision
- CMPX Strong Buy
- PROK Buy
- Analyst Count
- CMPX 3
- PROK 5
- Target Price
- CMPX $7.67
- PROK $4.50
- AVG Volume (30 Days)
- CMPX 421.2K
- PROK 430.9K
- Earning Date
- CMPX 11-12-2024
- PROK 11-12-2024
- Dividend Yield
- CMPX N/A
- PROK N/A
- EPS Growth
- CMPX N/A
- PROK N/A
- EPS
- CMPX N/A
- PROK N/A
- Revenue
- CMPX $850,000.00
- PROK N/A
- Revenue This Year
- CMPX N/A
- PROK N/A
- Revenue Next Year
- CMPX $610.48
- PROK N/A
- P/E Ratio
- CMPX N/A
- PROK N/A
- Revenue Growth
- CMPX N/A
- PROK N/A
- 52 Week Low
- CMPX $0.77
- PROK $1.18
- 52 Week High
- CMPX $2.34
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- CMPX 41.28
- PROK 37.52
- Support Level
- CMPX $1.44
- PROK $1.70
- Resistance Level
- CMPX $1.58
- PROK $2.03
- Average True Range (ATR)
- CMPX 0.12
- PROK 0.21
- MACD
- CMPX -0.01
- PROK -0.04
- Stochastic Oscillator
- CMPX 11.63
- PROK 0.74
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.